Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has been demonstrated to alleviate non-alcoholic fatty liver disease (NAFLD). The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.